Clinical trial · Observational
Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer
Serum Thioredoxin Reductase Activity Research in First-line Chemotherapy Advanced Non-small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In pre-clinical study we found that the thioredoxin reductase activity of serum harbours huge difference between cancer patients and non-cancer patients, the enzyme activity elevated remarkably among cancer patients, and after any kind of treatment serum thioredoxin reductase activity declined remarkably, so we hypothesis that serum thioredoxin reductase activity could be a warning marker for early progression of first-line treatment for advanced non-small cell lung cancer
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
| Carcinoembryonic Antigen | — | UNRESOLVED | — |
| First Line Treatment | — | UNRESOLVED | — |
| Progression | — | UNRESOLVED | — |
| Thioredoxin Reductase Activity | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- first line advanced non-small cell lung cancer
- description
- patients newly diagnosed advanced non-small cell lung cancer, and received platinum based chemotherapy in Hunan Province Tumor Hospital
Primary outcomes (1)
- measure
- To measure the thioredoxin reductase activity in blood
- timeFrame
- may 2013 - may 2014 (1 year)
- description
- 3-4 ml whole blood was obtained and then centrifuged and stored at -20 ℃, thioredoxin reductase activity was measured within 30 days using 5，5'-Dithio bis-（2-nitrobenzoic acid）(DTNB) method.
Secondary outcomes (1)
- measure
- To measure the carcinoembryonic antigen (CEA) level in blood
- timeFrame
- may 2013- may 2014 (1 year)
- description
- Measure the CEA level every time compared with thioredoxin reductase activity
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically proven non-small cell lung cancer, stage Ⅳ patients or unsuitable for local treatment of ⅢB stage patients * Malignant tumor treatment naive including surgery（except for surgery for cervical cancer and cutaneous squamous cell carcinoma 5 years before, except for lung cancer patients who received surgery and adjuvant chemotherapy after 12 month then diagnosed with stage ⅢB or Ⅳ） * Signed informed consent would like to provide blood for research Exclusion Criteria: * Patients received antitumor treatment before * Patients with contraindication of chemotherapy * Pregnant or breast feeding women
References
Publications (0)
Data not yet available